by Anna D. Sinaiko, Ph.D., and Meredith B. Rosenthal, Ph.D
Slowing the growth of health care costs is critical to the long-term fiscal stability of the United States and is the direct or indirect focus of most U.S. health policy initiatives today. One tactic for reducing spending is to increase price transparency in health care — to publish the prices that providers charge or those that a patient would pay for medical care — with the aim of lowering prices overall. More than 30 states are considering or pursuing legislation to increase price transparency (see table). Most initiatives focus on publishing average or median within-hospital prices for individual services, though information on total and out-of-pocket costs for episodes of care across different sites are available in some markets (e.g., New Hampshire). At the federal level, three bills designed to increase transparency were introduced in Congress in 2010 and attracted some early bipartisan support. In addition, several commercial health insurance plans release information to their members about the prices charged by hospitals and physicians for common services and procedures.
At one level, it’s the wide variation in medical prices within U.S. markets that creates an opportunity for transparency to reduce spending. This variation exists even for relatively common procedures. In New Hampshire in 2008, the average payment for arthroscopic knee surgery was $2,406 with a standard deviation of $1,203 in hospital settings and $2,120 with a standard deviation of $1,358 in nonhospital settings.1 In Massachusetts, the median hospital cost in 2006 and 2007 for magnetic resonance imaging (MRI) of the lumbar spine, performed without contrast material, ranged from $450 to $1,675.2
Since consumers are generally ignorant of such price differences, publishing price information could both narrow the range and lower the level of prices, in part by permitting consumers to engage in more cost-conscious shopping and select lower-cost providers and in part by stimulating price competition on the supply side, forcing high-priced providers to lower their prices (or accept smaller annual increases) in order to remain competitive. Proponents argue that consumers have price information and compare costs when purchasing just about any other good (imagine buying a car, a house, or a computer without knowing its price) and that health care should be no different.
Health care does differ from other consumer goods in a few important ways, however, that are likely to affect patients’ responses to price information.
More
This blog tracks aging and disability news. Legislative information is provided via GovTrack.us.
In the right sidebar and at the page bottom, bills in the categories of Aging, Disability, Medicare, Medicaid, and Social Security are tracked.
Clicking on the bill title will connect to GovTrack updated bill status.
Showing posts with label Public policy. Show all posts
Showing posts with label Public policy. Show all posts
Friday, March 11, 2011
Global Burden of Disease Study: Establishing Global Health Priorities

Please provide your feedback to the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 Health Measurement Survey.
The Global Burden of Disease Study of 2010
aims to measure the impact of different diseases, injuries, and risk
factors on people's health worldwide. This research updates a
groundbreaking study first published in 1993 that changed the way
researchers and health experts around the world thought about global
health priorities.
By participating in the survey, you will contribute to the scientific understanding of global health problems and ultimately enable policymakers and health care leaders to make better decisions based on stronger evidence. The survey takes about 15 minutes to complete. Your participation in this study is completely voluntary, and your responses will be anonymous.
Take the Survey

Wednesday, February 23, 2011
The Long Term Care Discussion Group
The Long Term Care Discussion Group
A voluntary independent group that meets solely for the purpose
of educating the policy community on all facets of long term care
Tuesday, March 15, 2011
10:30 a.m. Eastern Time
AARP Offices ~ 601 E Street, NW, Room B2-130
Recent
AARP Research: How LTC Is Weathering the State Financial Storm &
Trends in Disability, Community Living, and Caregiving
(Please note – you must RSVP in advance to get into the building)
Speakers:
Wendy Fox-Grage & Don Redfoot
Wendy Fox-Grage
is a Senior Strategic Policy Advisor for the AARP Public Policy
Institute. For the
past six years in this role, she has identified emerging policy issues
and developed policy options and reform strategies in long term services
and supports. She has conducted public policy research and provided
policy analysis and guidance to state AARP offices.
Previously, she was Program Principal for the National Conference of
State Legislatures. In that role, Wendy provided technical assistance
to state legislators, legislative staff, press and others on health care
issues, analyzed state and federal legislation
and monitored legislative trends. Wendy also was a Congressional
fellow with the U.S. Senate Special Committee on Aging and has both a
Master of Science in Gerontology and a Master of Public Administration
degree from the University of Southern California.
Donald L. Redfoot, Ph D. has
been a Strategic Policy Advisor with AARP’s Public Policy Institute for
the past 15 years. During that time, he has
conducted and supervised research on long term care and housing public
policy issues, including: assisted living, end-of-life care, trends in
disability and institutional care, international comparisons of long
term care systems, and reverse mortgages. He
has participated in numerous expert panels and boards, including
serving as a founding member and, for two years, Chairman of the Board
of the Center for Excellence in Assisted Living, an umbrella
organization of 11 national stakeholder organizations involved
with assisted living. Previously, he served for eight years as AARP’s
Legislative Representative on housing and transportation issues. Don
received his Ph.D. in sociology from Rutgers University, his M.A. in the
social sciences at the University of Chicago,
and his B.A. in sociology from Westminster College (PA). He has written
numerous reports and articles for academic, policy, and popular
audiences.
Please RSVP to Joyce Tower at
JTower@univitahealth.com
Long Term Care Discussion Group Co-Chairs:
Winthrop Cashdollar, John Cutler, Karl Polzer, Jill Randolph, and Eileen J. Tell
For more information about the Long Term Care Discussion Group, visit
www.ltcdiscussiongroup.org
Thursday, January 27, 2011
Long Term Care Discussion Group - New Website
The Long Term Care Discussion Group is an informal non-partisan networking group of long term care (LTC) policy stakeholders. It meets monthly in Washington, DC (with telephone access when logistics allow) to hear from policymakers, practitioners, researchers, advocates and others regarding long term care policy issues, research, education and advocacy. Participants include stakeholders from the LTC insurance industry, the provider community, researchers and academics, federal government agencies, Capitol Hill, consumer advocates and others.
Topics covered in recent years include: White House perspectives on LTC initiatives, the federal government's LTC consumer awareness efforts, House and Senate briefings on various Hill proposals and others. Research topics have included the Long Term Care Admissions Cohort Study, an analysis of the impact of state tax incentives for LTC insurance; and state requirements for in-home worker safety checks. Recent topics included a discussion of the newly enacted CLASS Act, Advance Directives, Caregiver Needs and Supports, and other topics.
Its website includes resource materials used by presenters in the monthly meetings.
Long Term Care Discussion Group
Topics covered in recent years include: White House perspectives on LTC initiatives, the federal government's LTC consumer awareness efforts, House and Senate briefings on various Hill proposals and others. Research topics have included the Long Term Care Admissions Cohort Study, an analysis of the impact of state tax incentives for LTC insurance; and state requirements for in-home worker safety checks. Recent topics included a discussion of the newly enacted CLASS Act, Advance Directives, Caregiver Needs and Supports, and other topics.
Its website includes resource materials used by presenters in the monthly meetings.
Long Term Care Discussion Group
Friday, January 14, 2011
UM Panel: Rethink End-of-Life Priorities - Health - MiamiHerald.com

As people live longer with the help of technological advances, end-of-life care will take an increasingly large bite out of the nation's healthcare budget -- unless we change the way we treat dying patients and their families, according to a panel Thursday at the University of Miami's Global Business Forum. Three medical doctors, a CEO and a professor of religious studies debated the economics and ethics of end-of-life decisions, warning that the care model historically used by the medical establishment needs to be improved in a world where there are more elderly people with more chronic illnesses. The emphasis, they agreed, should be on a team-oriented holistic approach tailored to the patient and his or her last wishes.
Full Article
Sunday, January 9, 2011
How Pharmaceutical Innovation Is Affected By Data Exclusivity Periods
Pharmaceutical companies and generic drug manufacturers have long been at odds over regulations about "data exclusivity," the period of time before generic manufacturers can make use of valuable clinical trial data.
A new study in the January 2011 issue of Health Affairs is the first to calculate the financial and social costs of limiting access to trial data - and finds that extending the term of exclusive access will lead to higher drug costs in the short term but also to more than 200 extra drug approvals and to greater life expectancy in the next several decades.
"Elected officials are unlikely to embrace legislation that would result in higher drug prices, but our research suggests that legislation to extend data exclusivity would spur innovation that would benefit future generations," explained Dana Goldman, lead author, director of the Schaeffer Center for Health Policy and Economics at USC and Norman Topping Chair in Medicine and Public Policy at USC.
Full Article
A new study in the January 2011 issue of Health Affairs is the first to calculate the financial and social costs of limiting access to trial data - and finds that extending the term of exclusive access will lead to higher drug costs in the short term but also to more than 200 extra drug approvals and to greater life expectancy in the next several decades.
"Elected officials are unlikely to embrace legislation that would result in higher drug prices, but our research suggests that legislation to extend data exclusivity would spur innovation that would benefit future generations," explained Dana Goldman, lead author, director of the Schaeffer Center for Health Policy and Economics at USC and Norman Topping Chair in Medicine and Public Policy at USC.
Full Article
Subscribe to:
Posts (Atom)